Novel canine models of obese prediabetes and mild type 2 diabetes

American Journal of Physiology - Endocrinology and Metabolism

Volumn 298, Issue 1, 2010, Pages

  Ionut, Viorica ^a   Liu, Huiwen ^a   Mooradian, Vahe ^a   Castro, Ana Valeria B ^a   Kabir, Morvarid ^a   Stefanovski, Darko ^a   Zheng, Dan ^a   Kirkman, Erlinda L ^a   Bergman, Richard N ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Animal models; Insulin secretion; Obesity; Streptozotocin

Indexed keywords

GLUCOSE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT; CELL FUNCTION; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; DOG; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ANIMALS; BODY COMPOSITION; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIETARY FATS; DISEASE MODELS, ANIMAL; DOGS; ENERGY INTAKE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; OBESITY; PREDIABETIC STATE; SEVERITY OF ILLNESS INDEX;

EID: 73649092371     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00466.2009     Document Type: Article

References (38)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 32: S62-S67, 2009.
2. Bell TD, DiBona GF, Wang Y, Brands MW. Mechanisms for renal blood flow control early in diabetes as revealed by chronic flow measurement and transfer function analysis. J Am Soc Nephrol 17: 2184-2192, 2006.
3. Bellinger DA, Merricks EP, Nichols TC. Swine models of type 2 diabetes mellitus: insulin resistance, glucose tolerance, and cardiovascular complications. ILAR J 47: 243-258, 2006.
4. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68: 1456-1467, 1981.
5. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 79: 790-800, 1987.
6. Bergman RN, Watanabe R, Rebrin K, Ader M, Steil G. Toward an integrated phenotype in pre-NIDDM. Diabet Med 13: S67-S77, 1996.
7. Bevilacqua S, Barrett EJ, Smith D, Simonson DC, Olsson M, Bratusch-Marrain P, Ferrannini E, DeFronzo RA. Hepatic and peripheral insulin resistance following streptozotocin-induced insulin deficiency in the dog. Metabolism 34: 817-825, 1985.
8. Black HE, Rosenblum IY, Capen CC. Chemically induced (streptozotocin-alloxan) diabetes mellitus in the dog. Biochemical and ultrastructural studies. Am J Pathol 98: 295-310, 1980.
9. Bradley DC, Steil GM, Bergman RN. OOPSEG: a data smoothing program for quantitation and isolation of random measurement error. Comput Methods Programs Biomed 46: 67-77, 1995.
10. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007 (Abstract). Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2009.
11. Centers for Disease Control and Prevention. 2009 National Diabetes Surveillance System (Online). http://www.cdc.gov/diabetes/ statistics/prev/ national/figpersons.htm [2009].
12. Colliard L, Ancel J, Benet JJ, Paragon BM, Blanchard G. Risk factors for obesity in dogs in France. J Nutr 136: 1951S-1954S, 2006.
13. Davis SN, Piatti PM, Monti L, Möller N, Ng LL, Coppack S, Antsiferov M, Brown MD, Alberti KG. A comparison of four methods for assessing in vivo beta-cell function in normal, obese and non-insulindependent diabetic man. Diabetes Res 19: 107-117, 1992.
14. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 444: 881-887, 2006.
15. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26, Suppl 1: S5-S20, 2003.
16. Finegood DT, Bergman RN, Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes 36: 914-924, 1987.
17. Finegood DT, Pacini G, Bergman RN. The insulin sensitivity index. Correlation in dogs between values determined from the intravenous glucose tolerance test and the euglycemic glucose clamp. Diabetes 33: 362-368, 1984.
18. Freyse EJ, Hahn von Dorsche H, Fischer U. Low dose streptozotocin diabetes after partial pancreatectomy in dogs. Histological findings in a new type of experimental diabetes. Acta Biol Med Ger 41: 1203-1210, 1982.
19. Hagman DK, Latour MG, Chakrabarti SK, Fontes G, Amyot J, Tremblay C, Semache M, Lausier JA, Roskens V, Mirmira RG, Jetton TL, Poitout V. Cyclical and alternating infusions of glucose and intralipid in rats inhibit insulin gene expression and Pdx-1 binding in islets. Diabetes 57: 424-431, 2008.
20. Hoenig M. Comparative aspects of diabetes mellitus in dogs and cats. Mol Cell Endocrinol 197: 221-229, 2002.
21. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42: 1663-1672, 1993.
22. Kim SP, Catalano KJ, Hsu IR, Chiu JD, Richey JM, Bergman RN. Nocturnal free fatty acids are uniquely elevated in the longitudinal development of diet-induced insulin resistance and hyperinsulinemia. Am J Physiol Endocrinol Metab 292: E1590-E1598, 2007.
23. Koopmans SJ, Mroz Z, Dekker R, Corbijn H, Ackermans M, Sauerwein H. Association of insulin resistance with hyperglycemia in streptozotocin-diabetic pigs: effects of metformin at isoenergetic feeding in a type 2-like diabetic pig model. Metabolism 55: 960-971, 2006.
24. Laflamme DP, Kealy RD, Schmidt DA. Estimation of body fat by body condition score (Abstract). J Vet Intern Med 8: 154, 1994.
25. Larsen MO, Wilken M, Gotfredsen CF, Carr RD, Svendsen O, Rolin B. Mild streptozotocin diabetes in the Göttingen minipig. A novel model of moderate insulin deficiency and diabetes. Am J Physiol Endocrinol Metab 282: E1342-E1351, 2002.
26. Masiello P. Animal models of type 2 diabetes with reduced pancreatic beta-cell mass. Int J Biochem Cell Biol 38: 873-893, 2006.
27. Mawby DI, Bartges JW, d'Avignon A, Laflamme DP, Moyers TD, Cottrell T. Comparison of various methods for estimating body fat in dogs. J Am Anim Hosp Assoc 40: 109-114, 2004.
28. McClain DA, Abraham D, Rogers J, Brady R, Gault P, Ajioka R, Kushner JP. High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia 49: 1661-1669, 2006.
29. Misawa K, Ichikawa K, Ojima K, Hamano S, Kitamura T, Komatsu H. Effect of KAD-1229, a nonsulfonylurea hypoglycemic agent, on plasma glucose and insulin in streptozotocin-induced diabetic dogs. Pharmacology 62: 65-72, 2001.
30. Mittelman SD, van Citters GW, Kim SP, Davis DA, Dea MK, Hamilton-Wessler M, Bergman RN. Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced betacell response. Diabetes 49: 2116-2125, 2000.
31. Ozaki K, Monnai M, Onoma M, Muramatsu H, Yogo K, Watanabe T, Oda Y, Katagiri K, Arakawa H, Itoh Z, Omura S, Takanashi H. Effects of mitemcinal (GM-611), an orally active erythromycin-derived prokinetic agent, on delayed gastric emptying and postprandial glucose in a new minipig model of diabetes. J Diabetes Complications 22: 339-347, 2008.
32. Rerup CC. Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol Rev 22: 485-518, 1970.
33. Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview. Indian J Med Res 125: 451-472, 2007.
34. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 52: 313-320, 2005.
35. Stockham SL, Scott MA. Fundamentals of Veterinary Clinical Pathology. Ames, IA: Iowa State Press, A Blackwell Publishing Company, 2002.
36. Thyssen S, Arany E, Hill DJ. Ontogeny of regeneration of beta-cells in the neonatal rat after treatment with streptozotocin. Endocrinology 147: 2346-2356, 2006.
37. Tobin BL, Finegood DT. Reduced insulin secretion by repeated low doses of STZ impairs glucose effectiveness but does not induce insulin resistance in dogs. Diabetes 42: 474-483, 1993.
38. Wagner JE, Kavanagh K, Ward GM, Auerbach BJ, Harwood HJ Jr, Kaplan JR. Old world nonhuman primate models of type 2 diabetes mellitus. ILAR J 47: 259-271, 2006.